ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders.
The annual meeting of stockholders of Abeona Therapeutics Inc.
(the Company) was held on May 15, 2017.The following matters were
acted upon:
1.ELECTION OF DIRECTORS
Todd Wider was elected to serve as director of the Company until
his successor is duly elected and qualified. The results of the
election of director is as follows:
| Nominee | Votes For | Votes Withheld | Broker Non-Votes |
| Todd Wider | 23,144,815 | 201,888 | 9,753,032 |
2. APPROVALTO AMEND OUR 2015 EQUITY INCENTIVE PLAN TO INCREASE
THE NUMBER OF SHARES OF OUR COMMON STOCK AUTHORIZED FOR ISSUANCE
UNDER THE PLAN FROM 8,000,000 TO 10,000,000 SHARES.
Approvalto amend our 2015 Equity Incentive Plan was approved by
the following votes:
| Votes For | Votes Against | Abstain | Broker Non-Votes |
| 20,924,214 | 2,170,583 | 362,262 | 9,753,032 |
3.RATIFICATION OF APPOINTMENT OF WHITLEY PENN LLP AS THE
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR
THE FISCAL YEAR ENDING DECEMBER 31, 2017.
Ratification of the appointment of Whitley Penn LLP as the
independent registered public accounting firm of the Company was
approved by the following votes:
| Votes For | Votes Against | Abstain | Broker Non-Votes |
| 31,640,063 | 82,196 | 1,487,832 |
Item 8.01. Other Events
On January 25, 2017, Abeona Therapeutics Inc. (the Company)
received a written notification from the Listing Qualifications
Department of The Nasdaq Stock Market LLC (Nasdaq) that the
Company had failed to comply with Nasdaqs independent director
requirement as set forth in Listing Rule5605.
On May 15, 2017, Abeona Therapeutics Inc. (the Company) received
a written notification from the Listing Qualifications Department
of The Nasdaq Stock Market LLC (Nasdaq) that Nasdaq has
determined that the Company has a majority independent board,
based on Mr. Jeffrey B. Davis not standing for reelection at the
Companys annual meeting on May 15, 2017, and as a result,
complies with Listing Rule 5605(b)(1) and the Company is back in
compliance with Nasdaq and this matter is now closed.
About ABEONA THERAPEUTICS INC. (NASDAQ:ABEO)
Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard. ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Recent Trading Information
ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) closed its last trading session up +0.05 at 6.00 with 397,006 shares trading hands.
